{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"341"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Duration of response (DoR) is defined as time from documentation of tumor response to disease progression according to the International Primary CNS Lymphoma Collaborative Group response assessment criteria.","groups":[{"description":"Subjects with relapsed primary central nervous system lymphoma (PCNSL) or relapsed secondary CNS lymphoma (SCNSL) without systemic disease will receive acalabrutinib until disease progression or unacceptable toxicity.","id":"OG000","title":"Open-label, Single-arm"}],"paramType":"NUMBER","populationDescription":"Participants who achieved a complete response were included.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"days"}